Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Baxter International Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $11.8B | |
|---|---|---|
| Revenue (ttm) | 11.5B | |
| Net income (ttm) | -1.1B | |
| EPS (ttm) | -$2.06 | |
| Shares out | 517M | |
| P/E (forward) | 11.2x | |
| Dividend | $0.04 (0.16%) | |
| Volume | 10,873,738 | |
| Beta | 0.65 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B | -1.9% |
| Gross profit | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B | -8.0% |
| Operating income | $1.35B | $-2.85B | $707.0M | $14.0M | $-308.0M | — |
| Net income | $1.28B | $-2.43B | $2.66B | $-649.0M | $-957.0M | — |
| EPS (diluted) | $2.53 | $-4.83 | $5.23 | $-1.27 | $-1.87 | — |
| EBITDA | $2.19B | $-1.76B | $1.73B | $1.12B | $766.0M | -23.1% |
| R&D | $531.0M | $450.0M | $518.0M | $590.0M | $518.0M | -0.6% |
| SG&A | $2.85B | $3.10B | $2.95B | $2.97B | $2.89B | +0.4% |
Recent company headlines from major financial publishers.
Under the base path, Baxter delivers gradual operational improvements where operating margins normalize toward historical levels and international healthcare tenders sustain volume demand. Shares reach $26.92 with an estimated return of 18.1% at an assigned likelihood of 45.0%. Confirmation requires meeting forward consensus adjusted diluted earnings targets.
The bull path envisions accelerated supply chain streamlining that restores operating profitability toward sector benchmarks, enabling rapid debt repayment and multiple expansion. Under this outcome, shares reach $35.73 delivering a return of 56.7% with a probability of 25.0%. Confirmation would appear through consecutive quarterly margin beats.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.8% | $30.9 | $30.9 | $30.9 | $30.9 | $30.9 |
| 6.8% | $28.8 | $28.8 | $28.8 | $28.8 | $28.8 |
| 7.8% | $26.9 | $26.9 | $26.9 | $26.9 | $26.9 |
| 8.8% | $25.1 | $25.1 | $25.1 | $25.1 | $25.1 |
| 9.8% | $23.4 | $23.4 | $23.4 | $23.4 | $23.4 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
